Lurbinectedin abrogates the expression of ASCL1 and NEUROD1 transcription factors and their target genes, such as BCL2, INSM1, MYC, and AURK in SCLC [248], which has been approved as a second-line therapy of SCLC by the FDA, with an ORR of 35% in patients with relapsed SCLC [249]. The gene discussed is BCL2; the disease is small cell lung carcinoma.